Cardiovascular disease and type 2 diabetes: Has the dawn of a new era arrived?

Diabetes Care

Volumn 40, Issue 7, 2017, Pages 813-820

  Abdul Ghani, Muhammad ^a,b   DeFronzo, Ralph A ^a   Del Prato, Stefano ^c   Chilton, Robert ^d   Singh, Rajvir ^b   Ryder, Robert E J ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HAMAD GENERAL HOSPITAL   (Qatar)

^c UNIVERSITY OF PISA   (Italy)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; PIOGLITAZONE; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCAGON LIKE PEPTIDE; GLUCOSIDE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMBINATION DRUG THERAPY; DRUG MECHANISM; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEART PROTECTION; HEMODYNAMICS; HUMAN; INSULIN SENSITIVITY; MAJOR ADVERSE CARDIAC EVENT; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; COMPLICATION; HYPERGLYCEMIA; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDES; GLUCOSIDES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 85021106117     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-2736     Document Type: Review

References (64)

1. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl. 2):S14-S21
2. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
3. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358: 2560-2572
4. DuckworthW, Abraira C,Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
5. UK ProspectiveDiabetes Study (UKPDS)Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853
6. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER SteeringCommittee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl JMed 2016;375: 311-322
7. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844
8. Zinman B, Wanner C, Lachin JM, et al.; EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
9. Kernan WN, Viscoli CM, Furie KL, et al.; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-1331
10. Dormandy JA, Charbonnel B, Eckland DJA, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289
11. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes.NEngl JMed 2008; 359:1577-1589
12. Hayward RA, Reaven PD, Wiitala WL, et al.; VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;372:2197-2206
13. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
14. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270-1287
15. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393
16. Obunai K, Jani S, Dangas GD. Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am 2007;91:1169-1184
17. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328
18. Simpson SH,Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. Can Med Assoc J 2006;174:169-174
19. Pladevall M, Riera-Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S. Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: metaanalysis of published observational studies. BMC Cardiovasc Disord 2016;16:14
20. Green JB, Bethel MA, Armstrong PW, et al.; TECOS StudyGroup. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
21. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 SteeringCommittee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
22. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
23. Eldor R, DeFronzo RA, Abdul-GhaniM. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care 2013;36(Suppl. 2):S162-S174
24. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333-3341
25. Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L; PROactive investigators. Impact of peripheral arterial disease in patients with diabetesdresults fromPROactive (PROactive 11). Atherosclerosis 2009;202:272-281
26. Ryder RE. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabet Med 2015;32:305-313
27. Nissen SE, Nicholls SJ, Wolski K, et al.; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-1573
28. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 2007;298: 1180-1188
29. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509-514
30. DruckerDJ. The biology of incretin hormones. Cell Metab 2006;3:153-165
31. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab 2016;24: 15-30
32. Nathanson D, Frick M, Ullman B, Nyström T. Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure. Diabetol Metab Syndr 2016;8:5
33. Liu L, Liu J, Huang Y. Protective effects of glucagon-like peptide 1 on endothelial function in hypertension. J Cardiovasc Pharmacol 2015; 65:399-405
34. Kumarathurai P, Anholm C, Larsen BS, et al. Effects of liraglutide on heart rate and heart rate variability: a randomized, double-blind, placebocontrolled crossover study. Diabetes Care 2017; 40:117-124
35. Smits MM, Muskiet MH, Tonneijck L, et al. GLP-1 receptor agonist exenatide increases capillary perfusion independent of nitric oxide in healthy overweight men. Arterioscler Thromb Vasc Biol 2015;35:1538-1543
36. ChenJW,Wang YL, LiHW. Elevated admission microalbuminuria predicts poor myocardial blood flow and 6-month mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Clin Cardiol 2012;35:219-224
37. Lønborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:1491-1499
38. Ussher JR, Baggio LL, Campbell JE, et al. Inactivation of the cardiomyocyte glucagonlike peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab 2014;3:507-517
39. Arturi F, Succurro E,Miceli S, et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine. 9 November 2016 [Epub ahead of print]. DOI: 10.1007/s12020-016-1166-4
40. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-965
41. Eriksson L, Saxelin R, Röhl S, et al. Glucagonlike peptide-1 receptor activation does not affect re-endothelialization but reduces intimal hyperplasia via direct effects on smooth muscle cells in a nondiabetic model of arterial injury. J Vasc Res 2015;52:41-52
42. Gaspari T,Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. Diab Vasc Dis Res 2013;10:353-360
43. Hirano T, Mori Y. Anti-atherogenic and antiinflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals. J Diabetes Investig 2016;7 (Suppl. 1):80-86
44. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study.Diabetes Care 2016;39:717-725
45. Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care 2016;39:e212-e213
46. Clarke GD, Molina-Wilkins M, Martinez S, et al. Improved left ventricular diastolic function (LVDF) following pioglitazone therapy is strongly related to increasedmyocardial insulin sensitivity. Diabetes 2014;63(Suppl. 1):A298
47. Abdul-GhaniMA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol 2015;309:F889-F900
48. Sarruf DA, Yu F, Nguyen HT, et al. Expression of peroxisome proliferator-activated receptorgamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 2009;150:707-712
49. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloridemonotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebocontrolled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-1611
50. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292:E871-E883
51. BajajM, Baig R, Suraamornkul S, et al. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:1916-1923
52. Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results fromthe Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015;17:268-275
53. Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016;4: 1004-1016
54. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307
55. Carbone LJ, Angus PW, YeomansND. Incretinbased therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and metaanalysis. J Gastroenterol Hepatol 2016;31:23-31
56. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-1031
57. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334
58. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000;58:2341-2350
59. DeFronzo RA, Tripathy D, SchwenkeDC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115
60. Merovci A,Mari A, Solis C, et al. Dapagliflozin lowers plasmaglucose concentration and improves b-cell function. J Clin EndocrinolMetab 2015;100: 1927-1932
61. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-1791
62. Bunck MC, Cornér A, Eliasson B, et al. Effects of exenatide on measures of b-cell function after 3 years inmetformin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2041-2047
63. Kapitza C, Dahl K, Jacobsen J, AxelsenM, Flint A. The effects of semaglutide on b-cell function in subjects with type 2 diabetes. Diabetes 2016;65 (Suppl. 1):A262
64. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adultswith type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016;4:411-419